» Articles » PMID: 7816824

Identification, Activity, and Structural Studies of Peptides Incorporating the Phorbol Ester-binding Domain of Protein Kinase C

Overview
Specialty Science
Date 1995 Jan 3
PMID 7816824
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The family of homologous enzymes known as protein kinase C (PKC) has been the object of intense interest because of its crucial role in cellular signal transduction. Although considerable information about the activation of PKC has been gained through structure-activity, molecular modeling, and synthetic studies of both natural and designed activators, information about the structure of PKC itself has been limited by its large size and requirement for phospholipid cofactors. Additionally, difficulties in the purification of truncated mutants of PKC have thus far prevented their analysis by nuclear magnetic resonance (NMR) or x-ray crystallographic methods. We describe the identification, synthesis, ligand-binding analysis, cofactor requirements, and preliminary NMR evaluation of two subdomains (peptides B and C) of the regulatory domain of PKC-gamma. Peptides B and C bind [3H]phorbol 12,13-dibutyrate with good affinity (Kd = 6.4 microM and 414 nM, respectively) in the presence of phosphatidylserine. In comparison, the binding affinity of [3H]phorbol 12,13-dibutyrate for PKC was found to be 2.6 nM. Like PKC itself, these peptides also recognize other PKC activators, including dioctanoylglycerol and teleocidin B-4, and exhibit an ability to differentiate phorbol ester from its C-4 epimer. NMR studies of PKC subdomains are also described, indicating that both peptides B and C are well behaved in solution and do not exhibit any concentration-dependent changes. Finally, these studies reveal that peptide B becomes conformationally ordered only in the presence of phospholipid, suggesting that the regulatory domain of PKC itself might be organized for activation only when associated with the lipid bilayer, where its activator (diacylglycerol) is encountered.

Citing Articles

Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV.

Gentry Z, McAteer O, Hamad J, Moran J, Kim J, Marsden M Sci Adv. 2025; 11(4):eads1911.

PMID: 39854456 PMC: 11778240. DOI: 10.1126/sciadv.ads1911.


REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment.

Yang H, Staveness D, Ryckbosch S, Axtman A, Loy B, Barnes A ACS Cent Sci. 2018; 4(1):89-96.

PMID: 29392180 PMC: 5785774. DOI: 10.1021/acscentsci.7b00475.


Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.

Ryckbosch S, Wender P, Pande V Nat Commun. 2017; 8(1):6.

PMID: 28232750 PMC: 5431895. DOI: 10.1038/s41467-016-0015-8.


Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.

Loy B, Lesser A, Staveness D, Billingsley K, Cegelski L, Wender P J Am Chem Soc. 2015; 137(10):3678-85.

PMID: 25710634 PMC: 4405261. DOI: 10.1021/jacs.5b00886.


Design, synthesis, and biological evaluation of diminutive forms of (+)-spongistatin 1: lessons learned.

Smith 3rd A, Risatti C, Atasoylu O, Bennett C, Liu J, Cheng H J Am Chem Soc. 2011; 133(35):14042-53.

PMID: 21761891 PMC: 3164888. DOI: 10.1021/ja2046167.


References
1.
Lee M, Bell R . Supplementation of the phosphatidyl-L-serine requirement of protein kinase C with nonactivating phospholipids. Biochemistry. 1992; 31(22):5176-82. DOI: 10.1021/bi00137a013. View

2.
Smith J, Smith L, Pettit G . Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun. 1985; 132(3):939-45. DOI: 10.1016/0006-291x(85)91898-4. View

3.
Mosior M, Epand R . Mechanism of activation of protein kinase C: roles of diolein and phosphatidylserine. Biochemistry. 1993; 32(1):66-75. DOI: 10.1021/bi00052a010. View

4.
Prendiville J, Crowther D, Thatcher N, Woll P, Fox B, McGown A . A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer. 1993; 68(2):418-24. PMC: 1968558. DOI: 10.1038/bjc.1993.352. View

5.
Philip P, Rea D, Thavasu P, Carmichael J, Stuart N, Rockett H . Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst. 1993; 85(22):1812-8. DOI: 10.1093/jnci/85.22.1812. View